About this trial
Familial Mediterranean Fever (FMF) is an autoinflammatory disease characterized by recurrent inflammatory attacks and persistent low-grade inflammation. Even during attack-free periods, subclinical inflammation may continue and contribute to long-term complications.
Advanced glycation end products (AGEs) are molecules that accumulate under chronic inflammatory and oxidative stress conditions. AGEs can be measured non-invasively using skin autofluorescence (SAF). The C-reactive protein-albumin-lymphocyte (CALLY) index is a composite marker derived from routine laboratory parameters and reflects systemic inflammation and nutritional status.
This observational cross-sectional study aims to evaluate the association between skin autofluorescence-measured AGE levels and the CALLY index in patients with FMF. The study will also compare AGE levels between FMF patients and age- and sex-matched healthy controls.
The study does not involve any intervention, treatment assignment, or randomization. All laboratory parameters will be obtained from routine clinical evaluations, and AGE measurement will be performed using a non-invasive device.
Eligibility criteria
Qualifiers
Age between 18 and 65 years
Diagnosis of Familial Mediterranean Fever according to Tel-Hashomer criteria
At least 6 months of clinical follow-up
Available routine laboratory data (CRP, albumin, lymphocyte count)
Disqualifiers
Diagnosis of diabetes mellitus
Chronic kidney disease stage 3 or higher
Active infection
Malignancy within the past 5 years
Trial design
Treatments tested in this trial
- Skin Autofluorescence Measurement